AlzeCure Pharma AB (publ) (FN STO: ALZCUR), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer’s disease and pain, today announced that the company will participate at Redeye Neurology Day on October 15, where CEO Martin Jönsson will present the company's development projects in neurology and provide an update on the recently signed agreements with Eli Lilly and QuantumCell.
Neurology Day is Redeye's annual event on drug development in neurology and brain diseases, areas with significant medical needs and where AlzeCure has several drug candidates in development. During 2026, the company has outlicensed two Alzheimer's projects: ACD680 from the Alzstatin platform to Eli Lilly, and ACD856 from the NeuroRestore platform to Denmark-based QuantumCell. In the presentation, Martin Jönsson will discuss the next steps in the partnerships and the company's remaining portfolio, including the Painless pain platform.
Presentation time: 11:15 CEST, October 15, 2026
Venue: Redeye, Mäster Samuelsgatan 42, Stockholm, Sweden
Watch the livestream via:
https://www.redeye.se/events/1145293/redeye-theme-neurology-4
The presentation will also be available afterwards on AlzeCure's company page at Redeye, www.redeye.se/company/alzecure-pharma, and on the company's website: https://www.alzecurepharma.se/en/presentations-and-interviews/
